Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

Asthma Clinical Trial

Official title:

The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals With Severe Asthma in the United States

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03373045
• Other study ID #: D3250R00023
• Status: Recruiting
• Start date: February 27, 2018
• Est. completion date: February 15, 2025

Study information

• Verified date: June 2024
• Source: AstraZeneca
• Contact: AstraZeneca Clinical Study Information Center
• Phone: 1-877-240-9479
• Email: information.center[@]astrazeneca.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. Data will be collected from the healthcare provider in a uniform manner for every patient enrolled using an electronic case report form (eCRF). Data will be collected monthly from patients via web-based surveys. Patients will be followed until study discontinuation or the patient withdraws from the study or death, whichever occurs first. The expectation is that patients will be followed for a period of at least 3 years.

Description:

The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. This study will provide a contemporary description of the epidemiology and medical management of United States adults with severe asthma who have not achieved control with high-dose ICS therapy and additional controllers. Additionally, the study will describe the use of and outcomes associated with recently approved monoclonal antibody therapies for severe asthma. Patients will be enrolled from a diverse population of academic and community-based specialist centers across the US. Data will be collected in a naturalistic manner and patient management will not be influenced by the study protocol. At least 1500 patients in the US with a confirmed diagnosis of severe asthma will be enrolled by a diverse set of asthma specialists (eg, allergists and pulmonologists who treat asthma) from academic and community-based centers. Basic de-identified information will be collected for all patients meeting study inclusion criteria, including those not approached for enrollment or who decline enrollment, to enable an assessment of the enrolled and non-enrolled populations. This information will include age, sex, insurance status, age at asthma diagnosis, class of asthma treatment per study inclusion criteria, number of asthma exacerbations in the past 12 months, study eligibility, whether the patient was approached for enrollment, study enrollment status, and reason for not enrolling for those who are approached but do not enroll. Patient-reported asthma control (Asthma Control Test [ACT]), asthma exacerbations, and treatment adherence will be solicited monthly. Patient-reported information on asthma-related healthcare utilization, global evaluation of treatment effectiveness (GETE), and work productivity (Work Productivity and Activity Impairment Asthma questionnaire [WPAI-Asthma]) will be collected at baseline and approximately every 3 months. Detailed information on asthma-related quality of life (Saint George's Respiratory Questionnaire [SGRQ]) as well as presence of an asthma treatment plan will be collected from patients approximately every 6 months. All of the questionnaires will be collected via web-based surveys. Patients will then be followed until study discontinuation or the patient withdraws from the study or death, whichever occurs first. The expectation is that patients will be followed for a period of at least 3 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. completion date: February 15, 2025
• Est. primary completion date: February 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 130 Years

Eligibility

Inclusion Criteria:

1. Individuals with a diagnosis of severe asthma for at least 12 months prior to enrollment and confirmed by the Investigator not to be due to alternative diagnoses.

2. Currently receiving care from specialist physicians (eg, pulmonologists and or allergists) at the Investigator's or sub-investigator's site.

3. 18 years of age and older. 4. Meeting at least one of the following three criteria (a, b, or c): a. Uncontrolled asthma while receiving high-dose ICS with additional controllers. i. Uncontrolled is defined by meeting at least one of the following (as outlined by ATS/ERS

[American Thoracic Society/European Respiratory Society] guidelines):

1. Poor symptom control: Asthma Control Questionnaire consistently =1.5, ACT <20 (or "not well controlled" by NAEPP [National Asthma Education and Prevention Program]/Global Initiative for Asthma guidelines).

2. Frequent severe exacerbations: two or more bursts of systemic corticosteroids (=3 days each) in the previous 12 months.

3. Serious exacerbations: at least one hospitalization, intensive care unit stay or mechanical ventilation in the previous 12 months.

4. Airflow limitation: after appropriate bronchodilator withhold FEV1 <80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal). ii. For the purposes of this study, high-dose ICS will be defined as

1. ICS at a cumulative dose of >500 µg fluticasone propionate equivalents daily as defined in Appendix A, or 2. Highest labeled dose of a combination of ICS/LABA. b. Current use of a Food and Drug Administration (FDA)-approved monoclonal antibody agent for treatment of severe asthma (use is not primarily for an alternative condition). c. Use of systemic corticosteroids or other systemic immunosuppressants (any dose level) for approximately 50% or more of the prior 12 months for treatment of severe asthma (use is not primarily for an alternative condition). Exclusion Criteria

1. Not willing and able to sign written informed consent. Consent can be obtained from having a responsible, legally authorized representative acting on patient's behalf.

2. Not fluent in English or Spanish.

3. Inability to complete study follow-up or web-based PROs. If the patient does not have email or web access, minimal assistance from others to access the web-based PRO is permitted (ie receiving the email and/or assisting patient in navigating to the web page); PROs must be completed by the patient.

4. Received an investigational therapy for asthma, allergy, atopic disease, or eosinophilic disease as part of a clinical trial during the 6 months prior to enrollment.

1. Once enrolled in the CHRONICLE Study, patients can enroll in trials of investigational therapies (as well as other non-interventional studies) as long as they continue to complete study follow-up. If a patient enrolls in a trial of an investigational therapy, the identity (National Clinical Trial [NCT] number) of the study and dates of the first and last investigational therapy administrations will be collected. If a patient receives blinded therapy in a trial, the Investigator will request the identity of that therapy at trial conclusion so that treatment information collected for the current study may be updated accordingly.

Related Conditions & MeSH terms

• Asthma

Locations

Country	Name	City	State
Puerto Rico	Research Site	Guaynabo
United States	Research Site	Albany	Georgia
United States	Research Site	Albuquerque	New Mexico
United States	Research Site	Altoona	Pennsylvania
United States	Research Site	Ann Arbor	Michigan
United States	Research Site	Ann Arbor	Michigan
United States	Research Site	Aransas Pass	Texas
United States	Research Site	Asheville	North Carolina
United States	Research Site	Aurora	Colorado
United States	Research Site	Bakersfield	California
United States	Research Site	Bayside	New York
United States	Research Site	Bellevue	Nebraska
United States	Research Site	Birmingham	Alabama
United States	Research Site	Birmingham	Alabama
United States	Research Site	Boise	Idaho
United States	Research Site	Brick	New Jersey
United States	Research Site	Bronx	New York
United States	Research Site	Bronx	New York
United States	Research Site	Bronx	New York
United States	Research Site	Bronx	New York
United States	Research Site	Brooklyn	New York
United States	Research Site	Brooklyn	New York
United States	Research Site	Burlington	Massachusetts
United States	Research Site	Chapel Hill	North Carolina
United States	Research Site	Charlotte	North Carolina
United States	Research Site	Chicago	Illinois
United States	Research Site	Chicago	Illinois
United States	Research Site	Chicago	Illinois
United States	Research Site	Clearwater	Florida
United States	Research Site	Clinton	South Carolina
United States	Research Site	Clinton Township	Michigan
United States	Research Site	Coral Gables	Florida
United States	Research Site	Corning	New York
United States	Research Site	Corvallis	Oregon
United States	Research Site	Dallas	Texas
United States	Research Site	Danbury	Connecticut
United States	Research Site	Decatur	Georgia
United States	Research Site	Denison	Texas
United States	Research Site	DuBois	Pennsylvania
United States	Research Site	Duncanville	Texas
United States	Research Site	Durham	North Carolina
United States	Research Site	Fayetteville	North Carolina
United States	Research Site	Flint	Michigan
United States	Research Site	Fort Worth	Texas
United States	Research Site	Gainesville	Georgia
United States	Research Site	Gainesville	Florida
United States	Research Site	Georgetown	Kentucky
United States	Research Site	Gilbert	Arizona
United States	Research Site	Great Neck	New York
United States	Research Site	Greenfield	Wisconsin
United States	Research Site	Greenville	South Carolina
United States	Research Site	Greenville	North Carolina
United States	Research Site	Hamtramck	Michigan
United States	Research Site	Harrisburg	Pennsylvania
United States	Research Site	Hendersonville	Tennessee
United States	Research Site	Hoover	Alabama
United States	Research Site	Houston	Texas
United States	Research Site	Houston	Texas
United States	Research Site	Houston	Texas
United States	Research Site	Iowa City	Iowa
United States	Research Site	Jacksonville	Florida
United States	Research Site	Kingwood	Texas
United States	Research Site	Kissimmee	Florida
United States	Research Site	Lake Mary	Florida
United States	Research Site	Lexington	Kentucky
United States	Research Site	Lexington	Kentucky
United States	Research Site	Lincoln	Nebraska
United States	Research Site	Lincoln	Rhode Island
United States	Research Site	Little Rock	Arkansas
United States	Research Site	Live Oak	Texas
United States	Research Site	Los Angeles	California
United States	Research Site	Louisville	Kentucky
United States	Research Site	Lynchburg	Virginia
United States	Research Site	Maplewood	Minnesota
United States	Research Site	Marlton	New Jersey
United States	Research Site	McKinney	Texas
United States	Research Site	Miami	Florida
United States	Research Site	Miami	Florida
United States	Research Site	Miami Beach	Florida
United States	Research Site	Mineola	New York
United States	Research Site	Mount Pleasant	South Carolina
United States	Research Site	Murray	Utah
United States	Research Site	New Brunswick	New Jersey
United States	Research Site	New Haven	Connecticut
United States	Research Site	New Hyde Park	New York
United States	Research Site	New Orleans	Louisiana
United States	Research Site	New Orleans	Louisiana
United States	Research Site	New Paltz	New York
United States	Research Site	New York	New York
United States	Research Site	Newport News	Virginia
United States	Research Site	Norfolk	Virginia
United States	Research Site	North Bergen	New Jersey
United States	Research Site	Northfield	New Jersey
United States	Research Site	Oklahoma City	Oklahoma
United States	Research Site	Omaha	Nebraska
United States	Research Site	Omaha	Nebraska
United States	Research Site	Omaha	Nebraska
United States	Research Site	Onalaska	Wisconsin
United States	Research Site	Overland Park	Kansas
United States	Research Site	Philadelphia	Pennsylvania
United States	Research Site	Pittsburgh	Pennsylvania
United States	Research Site	Plantation	Florida
United States	Research Site	Portland	Oregon
United States	Research Site	Portland	Oregon
United States	Research Site	Redondo Beach	California
United States	Research Site	Richmond	Virginia
United States	Research Site	Richmond	Virginia
United States	Research Site	Riverside	California
United States	Research Site	Rochester	New York
United States	Research Site	Rock Hill	South Carolina
United States	Research Site	Rockville	Maryland
United States	Research Site	Rockville Centre	New York
United States	Research Site	Roseville	California
United States	Research Site	Sacramento	California
United States	Research Site	Saint Louis	Missouri
United States	Research Site	Saint Petersburg	Florida
United States	Research Site	San Antonio	Texas
United States	Research Site	Sayre	Pennsylvania
United States	Research Site	Shreveport	Louisiana
United States	Research Site	Silver Spring	Maryland
United States	Research Site	Staten Island	New York
United States	Research Site	Studio City	California
United States	Research Site	Sugar Land	Texas
United States	Research Site	Tacoma	Washington
United States	Research Site	Tallahassee	Florida
United States	Research Site	Tampa	Florida
United States	Research Site	Toledo	Ohio
United States	Research Site	Toms River	New Jersey
United States	Research Site	Toms River	New Jersey
United States	Research Site	Valhalla	New York
United States	Research Site	Vancouver	Washington
United States	Research Site	Ventura	California
United States	Research Site	Verona	New Jersey
United States	Research Site	Waterbury	Connecticut
United States	Research Site	Wausau	Wisconsin
United States	Research Site	West Des Moines	Iowa
United States	Research Site	Westminster	California
United States	Research Site	Winston-Salem	North Carolina
United States	Research Site	Wyoming	Michigan
United States	Research Site	Yardley	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
AstraZeneca	MedImmune LLC, Parexel

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Healthcare utilization- hospitalizations, clinic Visits, and asthma exacerbations	Longitudinal changes of Healthcare utilization will be measured using directly collected information from medical, hospital, and pharmacy records to provide a supplementary comprehensive assessment of each patient's healthcare utilization during the study period.	At baseline, every 6 months, through study completion, assessed up to 7 years.
Primary	Asthma treatment	Asthma medications with dose and start/stop dates including all FDA-approved and standard of care treatments for asthma will be assessed. Longitudinal changes in asthma treatment will also be assessed.	At baseline, every 6 months, through study completion, assessed up to 7 years.
Primary	Treatment adherence	Extraction of electronic medical, hospital, and pharmacy records will take place at study close and potentially at interim time points to provide a supplementary assessment of each patient's healthcare resource utilization. Longitudinal changes in patient reported treatment adherence will also be assessed.	At baseline, every 1 month, through study completion, assessed up to 7 years.
Primary	Asthma control test (ACT)	Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).; In 2022, the ACT survey will be removed, and only the AIRQ will be solicited monthly.	Change from baseline, every 1 month, through study completion, assessed up to 4 years.
Primary	Patient-reported asthma exacerbations	Asthma exacerbations, the primary analytical definition will be worsening of asthma that leads to any of the following: Use of systemic corticosteroids (or a temporary increase in a stable corticosteroid background dose) for at least 3 days; a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids. An emergency department or urgent care visit (defined as evaluation and treatment for <24 hours in an emergency department or urgent care center) due to asthma that required systemic corticosteroids. An inpatient hospitalization (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for =24 hours) due to asthma.; In 2022, the asthma exacerbations survey will be removed, and only the AIRQ will be solicited monthly.	Change from baseline, every 1 month, through study completion, assessed up to 4 years.
Primary	Asthma Impairment and Risk Questionnaire (AIRQ)	AIRQ is a 10-item, equally weighted, yes/no composite asthma control questionnaire that includes 7 impairment and 3 risk items. AIRQ scores range from 0 to 10, with lower scores representing better controlled asthma.	At baseline, every 1 month, through study completion, assessed up to 4 years
Primary	Work Productivity and Activity Impairment Asthma questionnaire (WPAI-Asthma)	Patient-reported productivity impairment assessment including work productivity, activity impairment, and disability will be collected via the WPAI-Asthma. Information will only be collected from procedures that are part of the patient's routine clinical care. WPAI Asthma questionnaire is calculated from 0 to 10 score (0 indicates-Asthma had no effect on my work/ daily activities and 10 indicates Asthma completely prevented me from working score/ doing my daily activities).	At baseline, every 3 months, through study completion, assessed up to 7 years.
Primary	St. George's Respiratory Questionnaire (SGRQ)	Patient-reported assessment of asthma quality of life will be collected via the SGRQ. SGRQ, a disease specific health-related quality of life measure developed for both asthma and chronic obstructive pulmonary disease (COPD) patients. The SGRQ has 50 items and scores are calculated for 3 domains (symptoms, activity, and impact [psychosocial]) as well as total score.; Symptoms - this component is concerned with the effect of respiratory symptoms, their frequency and severity.; Impacts (psychosocial) - covers a range of aspects concerned with social functioning and psychological disturbances resulting from respiratory disease Activity - concerned with activities that cause or are limited by breathlessness. Total score summarizes the impact of the disease on overall health status.; The score is expressed as a percentage of overall impairment, where 100 represents worst possible health status and 0 indicates best possible health status.	At baseline, every 6 months, through study completion, assessed up to 7 years.
Primary	Global evaluation of treatment effectiveness (GETE)	Patient evaluation of asthma treatment effectiveness will be measured using GETE; a simple measure of perceived treatment effectiveness. The patient will grade the overall treatment effectiveness using the following criteria: excellent (complete control of asthma); good (marked improvement of asthma); moderate (discernible, but limited improvement in asthma); poor (no appreciable change in asthma); or worsening (of asthma).	At baseline, every 6 months, through study completion, assessed maximum up to 7 years.
Primary	Number of Participants With Adverse Events associated with corticosteroid therapy	Frequency of relevant medical events such as weight gain (change in BMI), hypertension, dyslipidemia, pneumonia, bone densitometry results, osteoporosis / osteopenia, hip and spinal fractures, avascular necrosis, cataract, glaucoma, diabetes mellitus, cardiovascular disease, Cushing's syndrome, adrenal insufficiency, peptic ulcer disease, myopathy, pseudotumor cerebri, mood disturbance, and insomnia or sleep disturbance.	At baseline, every 6 months, through study completion, assessed up to 7 years.
Primary	Relevant respiratory medical events	Frequency of relevant respiratory medical events such as pneumonia, pleural effusion, chronic bronchitis, allergic rhinitis.	At baseline, every 6 months, through study completion,assessed up to 7 years.
Primary	Respiratory comorbidities	Prevalence of respiratory comorbidities such as chronic obstructive pulmonary disease (COPD), bronchiectasis, alpha-1 anti-trypsin deficiency, Churg- Strauss syndrome (eosinophilic granulomatosis with polyangiitis [EGPA]), airway stenosis, cystic fibrosis, allergic bronchopulmonary aspergillosis,chronic eosinophilic pneumonia, bronchiolitis obliterans, immunodeficiency, primary ciliary dyskinesia, atelectasis, arterial hypertension, pulmonary hypertension, neuromuscular disease, allergic rhinitis, chronic rhinosinusitis, and pulmonary embolism.	At baseline, every 6 months, through study completion, assessed up to 7 years.
Primary	Non-respiratory comorbidities	Prevalence of non-respiratory comorbidities such as diabetes, thyroid disease, cardiac disease, etc.	At baseline, every 6 months, through study completion, assessed up to 7 years.
Primary	Events of special interest	Frequency of special interest events including new onset malignancy, severe infection, anaphylaxis, or mortality.	At baseline, every 6 months, through study completion, assessed up to 7 years.
Primary	Complete blood count with differential including blood eosinophil count.	To assess complete blood count with differential including blood eosinophil count as a variable for asthma evaluation.	Change from baseline, every 6 months, through study completion, assessed up to 7 years.
Primary	Total immunoglobulin E (IgE)	To assess total IgE as a variable for asthma evaluation.	Change from baseline, every 6 months, through study completion, assessed up to 7 years.
Primary	Radiographic changes in asthma evaluation.	Radiographic changes in asthma evaluation included chest X-rays (dates, views, description of major chest findings), Chest computed tomography scan (dates, high resolution (yes/no), intravenous contrast (yes/no), description of major findings). Radiographic asthma evaluation conducted as part of routine care.	Change from baseline, every 6 months, through study completion, assessed up to 7 years.
Primary	Forced Vital Capacity (FVC)	FEV1 (liters and % predicted) will be assessed as a variable for asthma evaluation.	Change from baseline, every 6 months, through study completion, assessed up to 7 years.
Primary	Forced Expiratory Volume in 1 second (FEV1)	FEV1 (liters and % predicted) will be assessed as a variable for asthma evaluation.	Change from baseline, every 6 months, through study completion, assessed up to 7 years.
Primary	Fractional exhaled nitric oxide (FENO)	To assess FENO as a variable for asthma evaluation.	Change from baseline, every 6 months, through study completion, assessed up to 7 years.